Cargando…

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma

Background: Recent advances in the development of tyrosine kinase inhibitors (TKIs) have enabled patients with unresectable hepatocellular carcinoma (HCC) to receive multiple TKIs in sequence. The aim of this study was to identify predictors of good candidates for second-line treatment after disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Takada, Hitomi, Kurosaki, Masayuki, Tsuchiya, Kaoru, Komiyama, Yasuyuki, Itakura, Jun, Takahashi, Yuka, Nakanishi, Hiroyuki, Yasui, Yutaka, Tamaki, Nobuharu, Maeyashiki, Chiaki, Kaneko, Shun, Takaura, Kenta, Higuchi, Mayu, Okada, Mao, Wang, Wan, Osawa, Leona, Sekiguchi, Shuhei, Hayakawa, Yuka, Yamashita, Koji, Enomoto, Nobuyuki, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770447/
https://www.ncbi.nlm.nih.gov/pubmed/31461985
http://dx.doi.org/10.3390/cancers11091256
_version_ 1783455475032915968
author Takada, Hitomi
Kurosaki, Masayuki
Tsuchiya, Kaoru
Komiyama, Yasuyuki
Itakura, Jun
Takahashi, Yuka
Nakanishi, Hiroyuki
Yasui, Yutaka
Tamaki, Nobuharu
Maeyashiki, Chiaki
Kaneko, Shun
Takaura, Kenta
Higuchi, Mayu
Okada, Mao
Wang, Wan
Osawa, Leona
Sekiguchi, Shuhei
Hayakawa, Yuka
Yamashita, Koji
Enomoto, Nobuyuki
Izumi, Namiki
author_facet Takada, Hitomi
Kurosaki, Masayuki
Tsuchiya, Kaoru
Komiyama, Yasuyuki
Itakura, Jun
Takahashi, Yuka
Nakanishi, Hiroyuki
Yasui, Yutaka
Tamaki, Nobuharu
Maeyashiki, Chiaki
Kaneko, Shun
Takaura, Kenta
Higuchi, Mayu
Okada, Mao
Wang, Wan
Osawa, Leona
Sekiguchi, Shuhei
Hayakawa, Yuka
Yamashita, Koji
Enomoto, Nobuyuki
Izumi, Namiki
author_sort Takada, Hitomi
collection PubMed
description Background: Recent advances in the development of tyrosine kinase inhibitors (TKIs) have enabled patients with unresectable hepatocellular carcinoma (HCC) to receive multiple TKIs in sequence. The aim of this study was to identify predictors of good candidates for second-line treatment after disease progression during sorafenib treatment. Methods: This is a retrospective cohort study of 190 consecutive HCC patients who were treated with sorafenib in our hospital. Three criteria of good candidates for second-line TKI at the time of disease progression during sorafenib treatment were defined as follows: criterion 1 was the same as the inclusion criteria of the regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) study, criterion 2 was the inclusion criteria of the RESORCE study plus Child–Pugh score 5, and criterion 3 was the inclusion criteria of the RESORCE study plus albumin–bilirubin (ALBI) grade 1. Factors at baseline and at week 4 during sorafenib treatment were used to predict patients fulfilling each of these three criteria. Results: The distribution of patients was 29%, 13%, and 6% in criteria 1, 2, and 3, respectively. Significant factors for meeting criterion 1 was the combination of baseline albumin >3.7 g/dL (odds ratio (OR) 2.7) plus degree of decrease in albumin (Δalbumin) at week 4 <0.2 g/dL (OR 2.6), or the combination of baseline ALBI score <−2.33 (OR 2.5) and ΔALBI at week 4 <0.255 (OR 4.9). For criterion 2, the value of baseline albumin and ALBI score was identical to criterion 1; however, Δalbumin (<0.1 g/dL) and ΔALBI score (<0.19) became stricter. For criterion 3, the value of baseline albumin (>3.8 g/dL) and ALBI (<−2.55) became stricter, as did Δalbumin (<0.1 g/dL) and ΔALBI (<0.085). Furthermore, tumor burden (>11) was selected as an additional predictor (OR 5.4). Conclusion: Predictors to satisfy the RESORCE study inclusion criteria were as follows: preserved liver function at baseline, as reflected by albumin or ALBI score, and small deterioration of liver function early during sorafenib therapy, as reflected by Δalbumin or ΔALBI at week 4. Liver function at baseline and degree of change in liver function during sorafenib treatment need to be stricter for better outcomes of liver function with disease progression.
format Online
Article
Text
id pubmed-6770447
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67704472019-10-30 Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma Takada, Hitomi Kurosaki, Masayuki Tsuchiya, Kaoru Komiyama, Yasuyuki Itakura, Jun Takahashi, Yuka Nakanishi, Hiroyuki Yasui, Yutaka Tamaki, Nobuharu Maeyashiki, Chiaki Kaneko, Shun Takaura, Kenta Higuchi, Mayu Okada, Mao Wang, Wan Osawa, Leona Sekiguchi, Shuhei Hayakawa, Yuka Yamashita, Koji Enomoto, Nobuyuki Izumi, Namiki Cancers (Basel) Article Background: Recent advances in the development of tyrosine kinase inhibitors (TKIs) have enabled patients with unresectable hepatocellular carcinoma (HCC) to receive multiple TKIs in sequence. The aim of this study was to identify predictors of good candidates for second-line treatment after disease progression during sorafenib treatment. Methods: This is a retrospective cohort study of 190 consecutive HCC patients who were treated with sorafenib in our hospital. Three criteria of good candidates for second-line TKI at the time of disease progression during sorafenib treatment were defined as follows: criterion 1 was the same as the inclusion criteria of the regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) study, criterion 2 was the inclusion criteria of the RESORCE study plus Child–Pugh score 5, and criterion 3 was the inclusion criteria of the RESORCE study plus albumin–bilirubin (ALBI) grade 1. Factors at baseline and at week 4 during sorafenib treatment were used to predict patients fulfilling each of these three criteria. Results: The distribution of patients was 29%, 13%, and 6% in criteria 1, 2, and 3, respectively. Significant factors for meeting criterion 1 was the combination of baseline albumin >3.7 g/dL (odds ratio (OR) 2.7) plus degree of decrease in albumin (Δalbumin) at week 4 <0.2 g/dL (OR 2.6), or the combination of baseline ALBI score <−2.33 (OR 2.5) and ΔALBI at week 4 <0.255 (OR 4.9). For criterion 2, the value of baseline albumin and ALBI score was identical to criterion 1; however, Δalbumin (<0.1 g/dL) and ΔALBI score (<0.19) became stricter. For criterion 3, the value of baseline albumin (>3.8 g/dL) and ALBI (<−2.55) became stricter, as did Δalbumin (<0.1 g/dL) and ΔALBI (<0.085). Furthermore, tumor burden (>11) was selected as an additional predictor (OR 5.4). Conclusion: Predictors to satisfy the RESORCE study inclusion criteria were as follows: preserved liver function at baseline, as reflected by albumin or ALBI score, and small deterioration of liver function early during sorafenib therapy, as reflected by Δalbumin or ΔALBI at week 4. Liver function at baseline and degree of change in liver function during sorafenib treatment need to be stricter for better outcomes of liver function with disease progression. MDPI 2019-08-27 /pmc/articles/PMC6770447/ /pubmed/31461985 http://dx.doi.org/10.3390/cancers11091256 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Takada, Hitomi
Kurosaki, Masayuki
Tsuchiya, Kaoru
Komiyama, Yasuyuki
Itakura, Jun
Takahashi, Yuka
Nakanishi, Hiroyuki
Yasui, Yutaka
Tamaki, Nobuharu
Maeyashiki, Chiaki
Kaneko, Shun
Takaura, Kenta
Higuchi, Mayu
Okada, Mao
Wang, Wan
Osawa, Leona
Sekiguchi, Shuhei
Hayakawa, Yuka
Yamashita, Koji
Enomoto, Nobuyuki
Izumi, Namiki
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
title Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
title_full Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
title_fullStr Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
title_full_unstemmed Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
title_short Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
title_sort baseline and early predictors of good patient candidates for second-line after sorafenib treatment in unresectable hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770447/
https://www.ncbi.nlm.nih.gov/pubmed/31461985
http://dx.doi.org/10.3390/cancers11091256
work_keys_str_mv AT takadahitomi baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT kurosakimasayuki baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT tsuchiyakaoru baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT komiyamayasuyuki baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT itakurajun baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT takahashiyuka baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT nakanishihiroyuki baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT yasuiyutaka baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT tamakinobuharu baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT maeyashikichiaki baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT kanekoshun baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT takaurakenta baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT higuchimayu baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT okadamao baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT wangwan baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT osawaleona baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT sekiguchishuhei baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT hayakawayuka baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT yamashitakoji baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT enomotonobuyuki baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma
AT izuminamiki baselineandearlypredictorsofgoodpatientcandidatesforsecondlineaftersorafenibtreatmentinunresectablehepatocellularcarcinoma